Abstracts tagged "Vasculitis"

Abstract Number: 0719 • ACR Convergence 2025
A Combined Transcriptomics and Proteomics Approach to Identify Immune Signatures in ANCA-Associated Glomerulonephritis
Ivana Stojkic¹, Arnon Arazi², Huijuan Song³, Pearlly Yan³, Estela Puchulu-Campanella³, Hubao Wang³, Lynn Fussner³, Brad Rovin⁴, Stacy Ardoin¹ and Salem Almaani³, ¹Nationwide Children's Hospital, Columbus, OH, ²The Feinstein Institutes for Medical Research, Manhasset, ³OSU, Columbus, OH, ⁴The Ohio State University, Columbus, OH
Background/Purpose: ANCA-associated vasculitis frequently involves the kidneys causing glomerulonephritis (AAGN). Despite advances in treatment, many patients develop end-stage kidney disease. An improved understanding of the…
Abstract Number: 0750 • ACR Convergence 2025
Fibrinogen as a biomarker in the diagnosis of giant cell arteritis and detection of flares
Jonathan Miller¹, Sharon Cowley², Patricia Harkins³, David O'Sullivan⁴, Gearoid McGeehan⁵, Eamonn Molloy⁶, Richard Conway⁷, David Kane⁸ and Geraldine mcCarthy⁹, ¹St Vincent's University Hospital, Dublin, Ireland, ²Tallaght University Hospital, Dublin, Dublin, Dublin, Ireland, ³Trinity College Dublin, Dublin ⁸, Dublin, Ireland, ⁴Tallaght University Hospital, Dublin, Dublin, Ireland, ⁵Mater Misericordiae University Hospital, Dublin, Dublin, Ireland, ⁶St Vincent's University Hospital, Dublin, Dublin, Ireland, ⁷Trinity College Dublin, Dublin, Dublin, Ireland, ⁸Tallaght University Hospital & Trinity College Dublin, D²⁴, Dublin, Ireland, ⁹Mater Misericordiae University Hospital, Dublin, Ireland
Background/Purpose: Giant cell arteritis (GCA) is the commonest idiopathic systemic vasculitis in adults over 50 years of age. It can be associated with high morbidity.…
Abstract Number: 0238 • ACR Convergence 2025
Real-World Effectiveness of Mepolizumab on Gastrointestinal Involvement in Eosinophilic Granulomatosis with Polyangiitis and Hypereosinophilic Syndrome: A Multicenter Retrospective Study
Alessia Gatti¹, Francesca Regola¹, Giulia Fontana², Jacopo Mora², Mario Andrea Piga³, Gianluca Moroncini³, Rossella Acquaviva⁴, Palma Carlucci⁴, Silvia Noviello⁴, Angelo Vacca⁴, Paolo Delvino⁵, Enrico Heffler⁶, Emanuele Nappi⁶, Jakub Moll⁷, Jan Schroeder⁷, Laura Losappio⁷, Federica Davanzo⁸, Roberto Padoan⁹, Paolo Cameli¹⁰, Edoardo Conticini¹¹, Greta Pacini¹², Alvise Berti¹², Lorenzo Vrola¹³, Paola Tomietto¹³, Benedetta Fazzi¹⁴, elena treppo¹⁵, Luca Quartuccio¹⁴, Jan Willem Cohen Tervaert¹⁶, Sabrina Arnold¹⁷, Prof. Dr. med. Peter Lamprecht¹⁸, Florence Roufosse¹⁹, Ilaria Cavazzana¹, Franco Franceschini²⁰, Giacomo Emmi²¹ and Paola Toniati²², ¹Rheumatology and Clinical Immunology Unit – ERN ReCONNET, ASST Spedali Civili of Brescia and University of Brescia, Brescia, Italy, ²Rheumatology and Clinical Immunology Unit – ERN ReCONNET, ASST Spedali Civili and University of Brescia, Brescia, Lombardia, Italy, ³Università Politecnica delle Marche and Azienda Ospedaliero Universitaria delle Marche, Ancona, Italy, ⁴Section of Internal Medicine 'Guido Baccelli', Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University of Bari 'Aldo Moro', Bari, Italy, ⁵Rheumatology Unit, IRCCS San Gerardo dei Tintori, Monza, Italy, ⁶Department of Biomedical Sciences, Humanitas University, Pieve Emanuele (MI) and Personalized Medicine, Asthma and Allergy, IRCCS Humanitas Research Hospital, Milano, Italy, ⁷Division of Allergy and Clinical Immunology, ASST GOM Niguarda, Milano, Italy, ⁸Rheumatology Unit, Department of Medicine DIMED, University of Padua, Padova, Italy, ⁹Rheumatology Unit, Department of Medicine DIMED, University of Padua, Padua, Italy, ¹⁰University of Siena, Siena, Italy, ¹¹Rheumatology Unit, Department of Medicine, Surgery and Neurosciences, University of Siena, Italy, Siena, Italy, ¹²Santa Chiara Hospital and University of Trento, Unit of Rheumatology, Trento, Italy, ¹³UCO Medicina Clinica, ASUGI, Cattinara Teaching Hospital, Trieste, Italy, ¹⁴Division of Rheumatology, Department of Medicine (DMED), University of Udine, Udine, Italy, ¹⁵Division of Rheumatology, Department of Medicine, University of Udine, Udine, Italy, ¹⁶University of Alberta, Edmonton, AB, Canada, ¹⁷Department of Rheumatology and Clinical Immunology, University of Lübeck, Lubeck, Germany, ¹⁸University of Lübeck, Lübeck, Germany, ¹⁹Department of Internal Medicine, Hôpital Universitaire de Bruxelles - Erasme, Université Libre de Bruxelles, Bruxelles, Belgium, ²⁰University of Brescia, Brescia, Brescia, Italy, ²¹Department of Medical, Surgical and Health Sciences, University of Trieste, Trieste, Italy, ²²Rheumatology and Clinical Immunology Unit – ERN ReCONNET, ASST Spedali Civili of Brescia, Brescia, Lombardia, Italy
Background/Purpose: Eosinophilic gastrointestinal disorders (EGIDs) are a group of disorders characterized by marked eosinophilic infiltration of the gastrointestinal (GI) tract resulting in organ dysfunction and…
Abstract Number: 2538 • ACR Convergence 2025
Comparative Study of Two Classification Criteria Sets in Real Clinical Practice in Behçet’s Disease
Rafael Gálvez Sánchez¹, José Luis Martín-Varillas², Lara Sánchez Bilbao³, Ivan Ferraz Amaro⁴, Carmen Lasa Teja⁵, Elena Aurrecoechea⁶, Diana Prieto-Peña⁷ and Ricardo Blanco³, ¹Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain, ²Rheumatology Division, Hospital de Laredo. IDIVAL, Immunopathology Group. Santander, Spain., Laredo, Spain, ³Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain, ⁴Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ⁵Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Riotuerto, Cantabria, Spain, ⁶Hospital Sierrallana, CANTABRIA, Spain, ⁷Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Santander, Spain
Background/Purpose: Behçet´s Disease (BD) was traditionally classified according to the International Study Group (ISG) in which oral ulcers were mandatory. International Team for the Revision…
Abstract Number: 1882 • ACR Convergence 2025
Vessels Under Fire: National Mortality Trends in Systemic Vasculitides in the United States, 1999–2020
Aziz-ur-Rahman Khalid¹, Ghassan Makhoul², Hasan Munshi², Islam Rajab², Emmanuel Olumuyide³, MD Walid Akram Hussain², Ahmed Huzien² and Robert Lahita⁴, ¹St. Joseph's University Medical Center, wayne, ²St. Josephs University Medical Center, Paterson, ³Advocate Illinois Masonic Medical Center, Chicago, ⁴St. Josephs University Medical Center, Wayne, NJ
Background/Purpose: Systemic vasculitides are rare but potentially life-threatening inflammatory disorders affecting blood vessels. Despite therapeutic advances, national mortality trends across vasculitis subtypes remain poorly defined.…
Abstract Number: 1612 • ACR Convergence 2025
Window of opportunity with tocilizumab therapy in giant cell arteritis. Multicenter study of 471 patients of clinical practice
Adrian Martin-Gutierrez¹, Javier Loricera², Diana Prieto-Peña³, Vicente Aldasoro Cáceres⁴, Olga Maiz⁵, Eugenio de Miguel⁶, Eva Galíndez Agirregoikoa⁷, Ivan Ferraz Amaro⁸, Santos Castañeda⁹ and Ricardo Blanco¹⁰, ¹Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Renedo de Piélagos, Spain, ²Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain, ³Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Santander, Spain, ⁴Hospital Universitario de Navarra, Pamplona, Spain, ⁵Hospital Universitario de Donosti, Donostia, Spain, ⁶Hospital Universitario La Paz, Madrid, Spain, ⁷BASURTO UNIVERSITY HOSPITAL, BILBAO, Spain, ⁸Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ⁹Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Madrid, Spain, ¹⁰Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain
Background/Purpose: Tocilizumab (TCZ) is the only biological drug currently approved for the treatment of giant cell arteritis (GCA), regardless of GCA duration. The “window of…
Abstract Number: 0717 • ACR Convergence 2025
Circulating Bacterial sRNAs are Altered in Patients with Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Christopher Xavier¹, Kevin Byram², Carol Langford³ and Michelle Ormseth⁴, ¹Meharry Medical College, Nashville, ²Vanderbilt University Medical Center, Nashville, TN, ³Cleveland Clinic, Moreland Hills, OH, ⁴Vanderbilt University Medical Center, Nashville
Background/Purpose: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (AAV) is an autoimmune disease causing small vessel inflammation. Underlying mechanisms of disease are unclear, but the human microbiota may…
Abstract Number: 0747 • ACR Convergence 2025
Patterns of Macrophage Polarization Induced by Serum from Patients with Giant Cell Arteritis and Takayasu’s Arteritis
Irene Carrión-Barberà¹, Ryan D. Stultz², David Cuthbertson³, Nader Khalidi⁴, Curry Koening⁵, Carol Langford⁶, Carol McAlear⁷, Paul Monach⁸, Larry Moreland⁹, Christian Pagnoux¹⁰, Philip Seo¹¹, Kenneth Warrington¹², Peter Merkel⁷ and Christian Lood¹³, ¹Department of Rheumatology. Hospital del Mar, Barcelona, Spain, ²University of Washington, Division of Rheumatology, Seattle, WA, ³University of South Florida, Tampa, ⁴Department of Medicine, McMaster University and St. Joseph’s Healthcare, Hamilton, Canada, ⁵University of Texas Dell Medical School, Austin, TX, ⁶Cleveland Clinic, Moreland Hills, OH, ⁷University of Pennsylvania, Philadelphia, PA, ⁸VA Boston Healthcare System, Boston, MA, ⁹University of Colorado, Denver, CO, ¹⁰Mount Sinai Hospital, University Health Network, Toronto, and Canadian Vasculitis Research Network (CanVasc), Toronto, ON, Canada, ¹¹Johns Hopkins University, Baltimore, MD, ¹²Mayo Clinic, ROCHESTER, MN, ¹³University of Washington, Division of Rheumatology, Seattle
Background/Purpose: Macrophages play a central role in the pathogenesis of large-vessel vasculitides, including giant cell arteritis (GCA) and Takayasu’s arteritis (TAK). Characterizing patterns of macrophage…
Abstract Number: 0206 • ACR Convergence 2025
Prospective Controlled Study of Humoral Response to Recombinant Zoster Vaccine in Cyclophosphamide-Treated Autoimmune Rheumatic Disease Patients: No Additional Impairment Compared to Other Immunosuppressive Therapies
Nadia Emi Aikawa¹, Julia Medeiros², Sandra G Pasoto³, Ana C Medeiros-Ribeiro³, Luciana Parente Costa Seguro⁴, Ana Paula Luppino-Assad⁵, Emily Figueiredo Neves Yuki⁶, Lissiane Guedes⁷, Clovis Artur Silva⁸ and Eloisa Bonfa⁴, ¹Rheumatology Division and Pediatric Rheumatology Unit, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Sao Paulo, São Paulo, Brazil, ²Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Sao Paulo, ³Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Sao Paulo, Brazil, ⁴Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, São Paulo, Brazil, ⁵Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, SAO PAULO, Brazil, ⁶Faculdade de Medicina da USP, São Paulo, São Paulo, Brazil, ⁷Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, ⁸University of São Paulo, São Paulo, São Paulo, Brazil
Background/Purpose: Recombinant zoster vaccine (RZV), represents a major advancement in the prevention of herpes zoster in autoimmune rheumatic diseases (ARD) patients. However, RVZ efficacy depends…
Abstract Number: 2537 • ACR Convergence 2025
Variation in Treatment Approaches in IgA-Vasculitis Among Pediatricians and Pediatric rheumatologists: A Cross-Sectional International Survey
Merav Heshin Bekenstein¹, Tali Elbaz², Yael Illous² and Barak Kandell³, ¹Tel Aviv Medical Center Israel, Binyamina, Tel Aviv, Israel, ²School of Medicine, Faculty of Medical and Health Sciences, Tel Aviv, Israel, ³The Academic College of Tel Aviv-Yafo, Tel Aviv, Israel
Background/Purpose: IgA Vasculitis (IgAV) is the most common small-vessel vasculitis in children. Although there is no evidence-based recommendations for treating IgAV, the European SHARE recommendations…
Abstract Number: 1767 • ACR Convergence 2025
Identification of C3 complement fragments in lesional tissues in ANCA-associated vasculitis
Claire Galand¹, Fei Liu², Katherine Vernon², Ravi Vats², Christine Lian³, V. Michael Holers⁴, H. Terence Cook⁵, David Cuthbertson⁶, Nader Khalidi⁷, Curry Koening⁸, Carol Langford⁹, Carol McAlear¹⁰, Paul Monach¹¹, Christian Pagnoux¹², Jason Campagna², Shelia Violette² and Peter Merkel¹⁰, ¹Q³² Bio Inc,, Waltham, MA, ²Q³² Bio Inc, Waltham, MA, ³Department of Pathology, Brigham & Women’s Hospital/Harvard Medical School, Boston, MA, ⁴University of Colorado Anschutz Medical Campus, Aurora, ⁵Department of Immunology and Inflammation, Imperial College London, London, United Kingdom, ⁶University of South Florida, Tampa, ⁷McMaster University, Hamilton, ON, Canada, ⁸University of Texas Dell Medical School, Austin, TX, ⁹Cleveland Clinic, Moreland Hills, OH, ¹⁰University of Pennsylvania, Philadelphia, PA, ¹¹VA Boston Healthcare System, Boston, MA, ¹²Mount Sinai Hospital, Toronto, ON, Canada
Background/Purpose: One proposed mechanism of tissue damage in ANCA-associated vasculitis (AAV) is the formation of neutrophil extracellular traps (NETs) during extravasation of neutrophils into and…
Abstract Number: 1607 • ACR Convergence 2025
Antibiotic Prophylaxis during Treatment of ANCA-associated Vasculitis with Rituximab: Data from a Multicenter Cohort
Natasha Le Blanc¹, Lillian Barra², Sasha Bernatsky³, Alison Clifford⁴, Mojtaba Dabaghjamanesh⁵, Natasha Dehghan⁶, Aurore Fifi-Mah⁷, Jean-Paul Makhzoum⁸, Nataliya Milman⁹, Medha Soowamber¹⁰, Nader Khalidi¹¹, Christian Pagnoux¹⁰, Rosalie-Selene Meunier¹², Jan Willem Cohen Tervaert⁴, Elaine Yacyshyn⁴ and Arielle Mendel¹³, ¹McGill University, Montreal, Canada, ²Western University, London, ON, Canada, ³Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ⁴University of Alberta, Edmonton, AB, Canada, ⁵Self employed, Richmond Hill, ON, Canada, ⁶University of British Columbia - Vancouver, Vancouver, BC, Canada, ⁷University of Calgary, Calgary, AB, Canada, ⁸Universite de Montreal, Montreal, Canada, ⁹the Ottawa Hospital, Ottawa, ON, Canada, ¹⁰Mount Sinai Hospital, Toronto, ON, Canada, ¹¹McMaster University, Hamilton, ON, Canada, ¹²Hopital du Sacre-Coeur-de-Montreal, Montreal, QC, Canada, ¹³McGill University Health Centre, Montréal, QC, Canada
Background/Purpose: Antibiotic prophylaxis is recommended during initial treatment of ANCA-associated vasculitis (AAV). We assessed characteristics associated with prophylaxis within a Canadian multicenter AAV cohort starting…
Abstract Number: 0715 • ACR Convergence 2025
Supervised machine learning algorithm to identify patients with eosinophilic granulomatosis with polyangiitis in France
Benjamin Terrier¹, Solenne Tauty², Anouar Salhi², Francoise Bugnard², Steve Benard², Vincent Cottin³, Camille Taillé⁴ and Xavier Puéchal⁵, ¹Cochin Hospital, Paris, France, ²Steve Consultants, Lyon, France, ³National Reference Center for Rare Pulmonary Diseases, Louis Pradel Hospital, Hospices Civils de Lyon, Claude Bernard University Lyon ¹, UMR ⁷⁵⁴, ERN-LUNG, Lyon, France, Lyon, France, ⁴Bichat hospital, APHP, Paris, France, ⁵Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hospital Cochin, and Université Paris Cité, Paris ( ⁷⁵⁰¹⁴ ), Ile-de-France, France
Background/Purpose: Identifying patients with eosinophilic granulomatosis with polyangiitis (EGPA) in claims databases such as the French National Health Data System (SNDS) is a major challenge…
Abstract Number: 0744 • ACR Convergence 2025
Age and Sex Influence on Clinical Manifestations of Giant Cell Arteritis: Results from the ARTESER Registry
Delia Fernandez-Lozano¹, Marta Domínguez-Álvaro², Javier Narváez³, Noemí Garrido⁴, Eugenio de Miguel⁵, Paula Estrada-Alarcón⁶, Iñigo Hernández-Rodríguez⁷, Maite Silva-Diaz⁸, Joaquín M Belzunegui⁹, Clara Moriano¹⁰, Julio Sánchez Martín¹¹, Itziar Calvo-Zorrilla¹², Vicente Aldasoro Cáceres¹³, lydia Abasolo Alcazar¹⁴, Javier Loricera¹⁵, rafeal Benito-Melero¹⁶, Maria Garcia-Villanueva¹⁷, Fernando Sánchez-Alonso², Santos Castañeda¹⁸, José L. Hernández¹⁹ and Ricardo Blanco²⁰, ¹Hospital Universitario y Politecnico La Fe, Valencia, Spain, ²Sociedad Española de Reumatología, Madrid, Spain, ³Hospital Universitario de Bellvitge, Barcelona, Spain, ⁴Hospital Universitario Virgen del Rocío, Sevilla, Andalucia, Spain, ⁵Hospital Universitario La Paz, Madrid, Spain, ⁶Hospital de San Juan Despí Moisès Broggi, Barcelona, Spain, ⁷Complejo Hospitalario Universitario de Vigo, Vigo, Spain, ⁸Complexo Hospitalario Universitario A Coruña, A Coruña, Galicia, Spain, ⁹Hospital Universitario Donostia, San Sebastian, Spain, ¹⁰Hospital León, LEON, Castilla y Leon, Spain, ¹¹Hospital Universitario ¹² de Octubre, Madrid, Spain, ¹²Galdakao-Usansolo University Hospital, Bilbao, Spain, ¹³Hospital Universitario de Navarra, Pamplona, Spain, ¹⁴IdISSC. HCSC, Madrid, Madrid, Spain, ¹⁵Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain, ¹⁶MD, barcelona, Spain, ¹⁷Hospital Ramón y Cajal, Madrid, Spain, ¹⁸Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Madrid, Spain, ¹⁹Instituto de Investigación Marqués de Valdecilla (IDIVAL), Universidad de Cantabria, Santander, Spain, ²⁰Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain
Background/Purpose: Giant cell arteritis (GCA) is a large vessel vasculitis that predominantly affects older adults, with a higher prevalence in women. Previous studies exploring sex-related…
Abstract Number: 0029 • ACR Convergence 2025
A Novel B Cell Subpopulation Characteristic of IgA Vasculitis Identified by Single-Cell RNA Sequencing
Joao Carlos Batista-Liz¹, María Sebastián Mora-Gil², Evan Troendle³, Oisin Cappa³, Maite Leonardo⁴, Ana Peñalba⁴, Luis mARTIN pENAGOS⁵, Ligia Gabrie-Rodriguez⁶, Rafael Gálvez Sánchez⁶, Jose Luis Callejas⁷, Belen Sevilla⁸, Diego de Argila⁹, Esther Vicente-Rabaneda⁹, Santos Castañeda¹⁰, David Simpson³, Ricardo Blanco¹¹, Verónica Pulito Cueto¹ and Raquel Lopez Mejias¹, ¹IDIVAL, Santander, Spain, ²Immunopathology Group, IDIVAL, Santander, Spain, ³Queens University, Wellcome-Wolfson Institute for Experimental Medicine, Belfast, United Kingdom, ⁴Division of Pediatrics, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁵Immunopathology Group, IDIVAL and Division of Nephrology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁶Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain, ⁷Department of Internal Medicine, Hospital San Cecilio, Granada, Spain, ⁸Division of Pediatrics, Hospital Universitario San Cecilio, Granada, Spain, ⁹Hospital Universitario de la Princesa, Madrid, Spain, ¹⁰Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Madrid, Spain, ¹¹Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain
Background/Purpose: IgA vasculitis (IgAV) is a systemic small-vessel vasculitis characterized by immune complex deposition containing aberrantly glycosylated IgA1. While its clinical manifestations are well defined…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].